



## **Cytori Reports Preclinical Results that Suggest Adipose-Derived Regenerative Cells may Reverse Periodontal Disease**

SAN DIEGO, Sep 14, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) reported results from their preclinical study on the use of uncultured adipose-derived regenerative cells (ADRCs) in the treatment of critical periodontal defects in a rat model. The results suggest that the use of ADRCs may reverse the effects of periodontal disease, evidenced by significantly improved alveolar bone healing and decreased gingival (gum) invasion of the defect. The data were reported today at the 95<sup>th</sup> Annual Meeting of the American Academy of Periodontology in Boston.

Severe periodontal disease (periodontitis) affects over 25% of the population in the U.S. alone. It is a painful condition that results in the decay of the bone and connective tissue that surround teeth that can ultimately lead to tooth loss. Currently, there is no generally accepted treatment with reliable results. These new study findings by Cytori may lead to new therapeutic treatments using ADRCs to treat and potentially reverse the effects of severe periodontitis.

As part of the study design, 20 immuno-deficient rats were treated for four critical defects in each. One of the defects was treated with uncultured human ADRCs and a second with cultured human adipose-derived stem cells (ADSC's), both in Platelet Rich Plasma (PRP). A third was treated with PRP alone and a fourth with no treatment.

The study's results showed that at six weeks post-treatment the defects treated with the uncultured ADRCs and with the cultured ADSCs showed a statistically significant ( $p < 0.001$ ) improvement in healing of the alveolar bone compared to the two controls. Furthermore, uncultured ADRC and cultured ADSC treatment significantly decreased the gingival invasion of the defect when compared to no treatment ( $p < 0.001$ ) and PRP alone ( $p < 0.05$ ).

### **About Cytori**

Cytori is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult stem and regenerative cells from adipose tissue. With the introduction of a family of medical devices, we have made a patient's own clinical grade stem and regenerative cells available to them at the point-of-care. The Celution<sup>(R)</sup> System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets, while we seek regulatory clearance for it in the United States. Our StemSource<sup>(R)</sup> product line is sold globally for cell banking and research applications. [www.cytoritx.com](http://www.cytoritx.com)

### **Cautionary Statement Regarding Forward-Looking Statements**

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical and preclinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.

SOURCE: Cytori Therapeutics

Cytori Therapeutics  
Tom Baker, 858-875-5258  
[tbaker@cytoritx.com](mailto:tbaker@cytoritx.com)

Copyright Business Wire 2009